Wave Life Sciences, Inc.
Wave Life Sciences is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. It develops RNA medicines, also called oligonucleotides, and therapies that target RNA for rare and common disorders. Its PRISM platform combines multiple RNA-targeting modalities, chemistry and human genetics. The toolkit includes RNA interference, RNA editing, antisense silencing and splicing, as well as bifunctional approaches that combine silencing with editing or upregulation. Wave’s clinical programs include WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency, WVE-008 for PNPLA3 I148M liver disease, WVE-N531 for Duchenne muscular dystrophy and WVE-003 for Huntington’s disease. It also advances preclinical programs and discovery research, including programs with GSK. The company develops and manufactures oligonucleotides through a hybrid internal and external manufacturing model, with internal manufacturing based in Lexington, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $WVE in the last 30 days.
See all $WVE insider activity →B. Riley Securities kept its Buy rating on Wave Life Sciences but reduced its price target from $22 to $18. This implies a 434.9% upside from the Nov 6 close of $3.37. Other recent analyst price targets for the company range from $11 to $44.
Canaccord Genuity kept its Buy rating on Wave Life Sciences and increased its price target to $44 from $42, suggesting a 1112.1% upside from the Oct 29 close of $3.63. Recent analyst price targets for the company range from $10 to $29.
Zura Bio (ZURA) shares rose 21% after Q3 2026 results and pipeline updates, with a net loss of $25.8M. Kiniksa (KNSA) gained 23% on strong Q3 revenue and raised ARCALYST revenue guidance. Pluri (PLUR) climbed 7% with a U.S. commercialization deal. Wave Life (WVE) advanced 8% on Q3 results and pipeline progress.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning WVE (Wave Life Sciences, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent WVE coverage spans financial news and earnings.
Analyst downgrade may pressure the stock lower.
The PT increase is likely to support near-term sentiment, but it is not a fundamental company catalyst by itself.
Revenue growth and pipeline advancement support a bullish view.
Quarterly loss widens but cash balance remains strong; upcoming trial data could drive future upside.
Positive cash position and progress on RNA‑editing programs suggest upside potential.
AlphAI scores every news story that mentions WVE with an AI model for sentiment and relevance, and aggregates insider trades from Wave Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
B. Riley Securities kept its Buy rating on Wave Life Sciences but reduced its price target from $22 to $18. This implies a 434.9% upside from the Nov 6 close of $3.37. Other recent analyst price targets for the company range from $11 to $44.
Canaccord Genuity kept its Buy rating on Wave Life Sciences and increased its price target to $44 from $42, suggesting a 1112.1% upside from the Oct 29 close of $3.63. Recent analyst price targets for the company range from $10 to $29.
Zura Bio (ZURA) shares rose 21% after Q3 2026 results and pipeline updates, with a net loss of $25.8M. Kiniksa (KNSA) gained 23% on strong Q3 revenue and raised ARCALYST revenue guidance. Pluri (PLUR) climbed 7% with a U.S. commercialization deal. Wave Life (WVE) advanced 8% on Q3 results and pipeline progress.
Wave Life Sciences reported Q3 2026 revenue of $13.2M and a net loss of $61.9M, with cash reserves of $431M expected to fund operations into Q3 2028. The company advanced clinical programs in obesity, AATD, and liver disease, with key milestones expected in Q4 2026. R&D expenses rose to $53.8M, and operational losses increased to $66M.
Wave Life Sciences, Inc. (WVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers Advancing WV
Wave Life Sciences reported Q3 2026 results, with $431.0M in cash and a runway into 3Q 2028. The company expects an additional $12M milestone in 4Q 2026. Key catalysts include clinical data and regulatory milestones for WVE-006.
WAVE Life Sciences (WVE) presented obesity data, highlighting reductions in visceral and subcutaneous fat. The company's Phase II-A study of WVE-007 is underway, assessing obesity and cardiometabolic outcomes. Wave also aligned with the FDA on a trial design for its alpha-1 antitrypsin deficiency program, aiming for a two-year clinical trial with a potential interim analysis at one year.
Analysts are discussing five stocks: Netflix (NFLX) with a Buy rating and $85 target, CarMax (KMX) upgraded to Buy with a $65 target, Workday (WDAY) downgraded to Hold, Wave Life Sciences (WVE) initiated with a Buy rating and $8.37 valuation, and FTAI Aviation (FTAI) with a Buy rating and $305 target.
William Blair initiated coverage on Wave Life Sciences (WVE) with an Outperform rating and a $8.37 valuation. The company is developing WVE-006 for alpha-1 antitrypsin deficiency and WVE-007 for obesity. William Blair projects 2036 sales of $606M for WVE-006 and $324M for WVE-007. WVE reported Q2 2026 earnings missing expectations, with a loss of $0.34 per share and revenue of $2.3M. The company has $490.6M in cash and marketable securities.
Wave Life Sciences (WVE) received a 'Buy' rating and $11.00 price target from UBS. The stock is trading at a 14.9% discount to its GF Value™ of $3.75, according to GuruFocus. WVE has a GF Score™ of 61/100, with strong growth potential but low profitability. 5 gurus hold the stock, with 4 increasing their positions.
